While the high ranking suggests NSCLC as a prime candidate for new anti-CTLA-4 antibodies, it is worth considering the fact that multiple randomized trials have failed to show significant improvement in survival of patients receiving Ipilimumab in combination with chemotherapy [8]. This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.